CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale Director sold 1,225,784 shares at an average $26.64 ($32,658,518)
- 4 Open-market sale Director sold 1,225,784 shares at an average $26.64 ($32,658,518)
- 4 Open-market sale Director by Deputization sold 1,225,784 shares at an average $26.64 ($32,658,518)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market sale President & CIO sold 339,441 shares at $26.47 ($8,985,003)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Shares withheld for taxes Director gave up 122 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 124 shares (to pay taxes)
- 4 Shares withheld for taxes Director gave up 54 shares (to pay taxes)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $21.92 ($4,384,000)
- 144 Insider Sale of Securities
- 4 Open-market sale President & CIO sold 1,330,868 shares at an average $21.72 ($28,902,500)
- 144 Insider Sale of Securities
- 4 Grant or award President and Vant Chair acquired 175,380 shares (grant or award)
Page 8 of 51 · 1,008 filings